138 related articles for article (PubMed ID: 31186846)
1. Predicting the response to the treatment of hepatitis C virus infection.
Thomas DL
Clin Liver Dis (Hoboken); 2012 Apr; 1(2):46-48. PubMed ID: 31186846
[No Abstract] [Full Text] [Related]
2. Review article: predicting response in hepatitis C virus therapy.
Mihm U; Herrmann E; Sarrazin C; Zeuzem S
Aliment Pharmacol Ther; 2006 Apr; 23(8):1043-54. PubMed ID: 16611264
[TBL] [Abstract][Full Text] [Related]
3. Panel reactive antibodies in predicting hepatitis C virus treatment outcome in kidney transplant candidates.
Öcal S; Harmancı Ö; Korkmaz M; Ensaroğlu F; Çolak T; Selçuk H; Moray G; Haberal M
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():193-6. PubMed ID: 25894153
[TBL] [Abstract][Full Text] [Related]
4. Association of Interferon Alpha Receptor 1 with sustained virological response in hepatitis C and B co-infected patients.
Asim M; Rashid A; Majeed A; Wahid M; Razak S; Jamil A
J Pak Med Assoc; 2017 Jul; 67(7):980-985. PubMed ID: 28770872
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon.
Thomas HC; Karayiannis P; Brook G
J Hepatol; 1991; 13 Suppl 1():S4-7. PubMed ID: 1960378
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of hepatitis B virus infection through serological and virological markers.
Kao JH
Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):553-62. PubMed ID: 19072403
[TBL] [Abstract][Full Text] [Related]
7. Role of viral and host factors in HCV persistence: which lesson for therapeutic and preventive strategies?
Missale G; Cariani E; Ferrari C
Dig Liver Dis; 2004 Nov; 36(11):703-11. PubMed ID: 15570998
[TBL] [Abstract][Full Text] [Related]
8. Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.
Su PY; Yen HH; Hsu YC; Wu SS; Kor CT; Su WW
Kaohsiung J Med Sci; 2016 Jul; 32(7):381-6. PubMed ID: 27450028
[TBL] [Abstract][Full Text] [Related]
9. [Non-invasive diagnostic methods of fibrosis in chronic hepatitis C virus infection: their role in treatment indication, follow-up and assessment of prognosis].
Pár A; Vincze Á; Pár G
Orv Hetil; 2015 May; 156(21):855-61. PubMed ID: 26038993
[TBL] [Abstract][Full Text] [Related]
10. miRNAs regulate immune response and signaling during hepatitis C virus infection.
Zhu H; Geng Y; He Q; Li M
Eur J Med Res; 2018 Apr; 23(1):19. PubMed ID: 29669594
[TBL] [Abstract][Full Text] [Related]
11. Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.
Kwo PY; Puenpatom A; Zhang Z; Hui SL; Kelley AA; Muschi D
PLoS One; 2019; 14(8):e0218759. PubMed ID: 31437170
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C viral kinetics during treatment of hepatitis C virus/HIV coinfected patients.
Zeremski M; Talal AH
Curr Opin HIV AIDS; 2007 Nov; 2(6):489-95. PubMed ID: 19372932
[TBL] [Abstract][Full Text] [Related]
13. Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C.
Kim MN; Kim HS; Kim JK; Kim BK; Kim SU; Park JY; Kim do Y; Ahn SH; Han KH
J Korean Med Sci; 2016 Sep; 31(9):1431-7. PubMed ID: 27510387
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B and C virus infections in the immune compromised.
Haydon GH; Mutimer DJ
Curr Opin Infect Dis; 2003 Oct; 16(5):473-9. PubMed ID: 14502001
[TBL] [Abstract][Full Text] [Related]
15. Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course.
Vallisa D; Bertè R; Rocca A; Civardi G; Giangregorio F; Ferrari B; Sbolli G; Cavanna L
Am J Med; 1999 May; 106(5):556-60. PubMed ID: 10335728
[TBL] [Abstract][Full Text] [Related]
16. New infection with heterotypic hepatitis C virus in a patient with long-term hepatitis C virus eradication.
De Mitri MS; Cassini R; Morsica G; Bagaglio S; Zoli M; Bernardi M
Dig Liver Dis; 2001 Oct; 33(7):591-4. PubMed ID: 11816550
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.
Abd-Elsalam S; Badawi R; Elnawasany S; Yousef M; Mansour L; Hawash N; Elkhouly RA; Soliman S; Selim A; Kobtan A; Elfert A
Infect Disord Drug Targets; 2019; 19(2):179-184. PubMed ID: 30207250
[TBL] [Abstract][Full Text] [Related]
18. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.
Promrat K; McDermott DH; Gonzalez CM; Kleiner DE; Koziol DE; Lessie M; Merrell M; Soza A; Heller T; Ghany M; Park Y; Alter HJ; Hoofnagle JH; Murphy PM; Liang TJ
Gastroenterology; 2003 Feb; 124(2):352-60. PubMed ID: 12557141
[TBL] [Abstract][Full Text] [Related]
19. Cellular immune response in patients with chronic hepatitis B virus infection.
Li X; Wang Y; Chen Y
Microb Pathog; 2014 Sep; 74():59-62. PubMed ID: 25128091
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.
Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):26-30. PubMed ID: 24199625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
